Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

91.92EUR
1:24pm BST
Change (% chg)

€-0.78 (-0.84%)
Prev Close
€92.70
Open
€92.61
Day's High
€93.46
Day's Low
€91.77
Volume
1,146,103
Avg. Vol
3,339,991
52-wk High
€94.40
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.64
Market Cap(Mil.): €122,735.20
Shares Outstanding(Mil.): 1,324.14
Dividend: 2.85
Yield (%): 3.07

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.89 40.53 41.01
EPS (TTM): 3.32 -- --
ROI: 5.49 16.83 16.17
ROE: 7.77 17.37 17.02
Search Stocks

Sanofi chairman says acquisitions not 'indispensable' for future

PARIS - French pharmaceutical company Sanofi has examined acquisitions opportunities but does not view deal-making as "indispensable" to its future, its chairman told French paper Les Echos in an interview.

30 Mar 2015

Sanofi chairman says acquisitions not 'indispensable' for future

PARIS - French pharmaceutical company Sanofi has examined acquisitions opportunities but does not view deal-making as "indispensable" to its future, its chairman told French paper Les Echos in an interview.

30 Mar 2015

Sanofi chairman says acquisitions not 'indispensable' for future

PARIS, March 30 - French pharmaceutical company Sanofi has examined acquisitions opportunities but does not view deal-making as "indispensable" to its future, its chairman told French paper Les Echos in an interview.

30 Mar 2015

Sanofi to launch Toujeo diabetes drug in U.S. on Monday: source

PARIS - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter.

27 Mar 2015

Sanofi to launch Toujeo diabetes drug in U.S. on Monday -source

PARIS, March 27 - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter.

27 Mar 2015

BRIEF-Sanofi Pasteur's Gardasil 9 HPV vaccine gets positive opinion from EMA

* Says Gardasil 9, new HPV vaccine from Sanofi Pasteur MSD granted positive opinion by European Ccommittee for Medicinal Products for Human Use

27 Mar 2015

CORRECTED-U.S. FDA again expands usage of Regeneron eye drug Eylea

March 25 - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults.

25 Mar 2015

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

LONDON - Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

23 Mar 2015

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

LONDON - Bristol-Myers Squibb , Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus (670 million pounds-plus) sales potential, according to a Thomson Reuters analysis.

23 Mar 2015

UPDATE 1-Bristol, Sanofi and Novartis drugs to shine among 2015 launches

* Up from three potential $1 billion-plus drugs in 2014 (Updates with link to report, paragraph 5)

23 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Finlabo SIM Spa
£7.00
Provider: S&P Capital IQ – STARS Reports
£82.00
Provider: Reuters Investment Profile
£10.00
Provider: Reuters Investment Profile
£10.00
Provider: Ford Investor Services, Inc.
£8.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks